Complexo Hospitalario Universitario de Santiago-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2019

  1. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

    Clinical Epigenetics, Vol. 11, Núm. 1

  2. Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: An estimation of life years and disease-free life years gained since its approval

    Oncotarget, Vol. 10, Núm. 42, pp. 4321-4332

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2014

  1. Zoledronic acid in the treatment of metastatic breast cancer

    Anti-Cancer Drugs, Vol. 25, Núm. 1, pp. 1-7

2013

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16

  2. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375